313 related articles for article (PubMed ID: 27011299)
1. Advances in patent applications related to allergen immunotherapy.
Silva ES; Pinheiro CS; Quintella CM; Ferreira F; C Pacheco LG; Alcântara-Neves NM
Expert Opin Ther Pat; 2016 Jun; 26(6):657-68. PubMed ID: 27011299
[TBL] [Abstract][Full Text] [Related]
2. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
Focke M; Swoboda I; Marth K; Valenta R
Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
[TBL] [Abstract][Full Text] [Related]
3. New strategies for allergen immunotherapy.
Carnés J; Robinson DS
Recent Pat Inflamm Allergy Drug Discov; 2008 Jun; 2(2):92-101. PubMed ID: 19075996
[TBL] [Abstract][Full Text] [Related]
4. Allergen-related approaches to immunotherapy.
Rolland JM; Gardner LM; O'Hehir RE
Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
6. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
Crameri R
Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
[TBL] [Abstract][Full Text] [Related]
7. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
Wilcock LK; Francis JN; Durham SR
Immunol Allergy Clin North Am; 2006 May; 26(2):333-47, viii-ix. PubMed ID: 16701148
[TBL] [Abstract][Full Text] [Related]
8. Engineered allergens for immunotherapy.
Bhalla PL; Singh MB
Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):569-73. PubMed ID: 15640701
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
Linhart B; Valenta R
Vaccine; 2012 Jun; 30(29):4328-35. PubMed ID: 22100888
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.
Valenta R; Vrtala S; Focke-Tejkl M; Bugajska-Schretter ; Ball T; Twardosz A; Spitzauer S; Grönlund H; Kraft D
Biol Chem; 1999; 380(7-8):815-24. PubMed ID: 10494830
[TBL] [Abstract][Full Text] [Related]
11. Immunological mechanisms of allergen-specific immunotherapy.
Larché M; Akdis CA; Valenta R
Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509
[TBL] [Abstract][Full Text] [Related]
12. A review of allergy and allergen specific immunotherapy.
Bidad K; Nicknam MH; Farid R
Iran J Allergy Asthma Immunol; 2011 Mar; 10(1):1-9. PubMed ID: 21358009
[TBL] [Abstract][Full Text] [Related]
13. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.
van Neerven RJ; Knol EF; Ejrnaes A; Würtzen PA
Int Arch Allergy Immunol; 2006; 141(2):119-29. PubMed ID: 16864979
[TBL] [Abstract][Full Text] [Related]
14. Allergen-specific T lymphocytes as targets for specific immunotherapy: striking at the roots of type I allergy.
Bohle B
Arch Immunol Ther Exp (Warsz); 2002; 50(4):233-41. PubMed ID: 12371619
[TBL] [Abstract][Full Text] [Related]
15. Novel vaccines for allergen-specific immunotherapy.
Akinfenwa O; Rodríguez-Domínguez A; Vrtala S; Valenta R; Campana R
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):86-99. PubMed ID: 33369572
[TBL] [Abstract][Full Text] [Related]
16. Allergen immunotherapy.
Huggins JL; Looney RJ
Am Fam Physician; 2004 Aug; 70(4):689-96. PubMed ID: 15338781
[TBL] [Abstract][Full Text] [Related]
17. Allergen-specific immunotherapy: an update on immunological mechanisms of action.
Ciprandi G; Marseglia GL; Tosca MA
Monaldi Arch Chest Dis; 2006 Mar; 65(1):34-7. PubMed ID: 16700191
[TBL] [Abstract][Full Text] [Related]
18. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.
Valenta R; Linhart B; Swoboda I; Niederberger V
Allergy; 2011 Jun; 66(6):775-83. PubMed ID: 21352238
[TBL] [Abstract][Full Text] [Related]
19. Bee Venom Immunotherapy: Current Status and Future Directions.
Zahirović A; Luzar J; Molek P; Kruljec N; Lunder M
Clin Rev Allergy Immunol; 2020 Jun; 58(3):326-341. PubMed ID: 31240545
[TBL] [Abstract][Full Text] [Related]
20. Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy.
Asturias JA
Front Biosci (Landmark Ed); 2009 Jan; 14(12):4606-17. PubMed ID: 19273375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
